Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
Open Access
- 17 January 2019
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 24 (3), 1800698-22
- https://doi.org/10.2807/1560-7917.es.2019.24.3.1800698
Abstract
The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.Keywords
This publication has 6 references indexed in Scilit:
- Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir MarboxilFrontiers in Microbiology, 2018
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and AdolescentsThe New England Journal of Medicine, 2018
- Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxilScientific Reports, 2018
- Influenza antivirals currently in late‐phase clinical trialInfluenza and Other Respiratory Viruses, 2017
- Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012.2012
- Influenza Virus Susceptibility and Resistance to OseltamivirAntiviral Therapy, 2005